Clinical Trials

Clinical trials are an essential step in bringing innovative drug candidates to the patient. They aim to assess the safety and efficacy of a new drug and are performed under the strict guidance and control of regulatory agencies such as the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan, Food and Drug Administration (FDA) in the US or the European Medicines Agency (EMA) in Europe.

Planned Clinical Trials

A phase 1 trial of UI-102 (TLR7/8 agonist encapsulated in PNP) as monotherapy or combination with immune checkpoint inhibitors for the treatment of advance, refractory solid tumors. The study will be initiated mid-2025

Completed Clinical Trials

A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine (UI-201) for the treatment of advanced soft tissue sarcoma

We want to provide you with the most important information and services in the best possible way. In order to do this, we need your consent to use the web analysis tool »Google Analytics« to create and evaluate an anonymous analysis of your visit for statistical purposes. You can change your consent at any time on the data protection page, otherwise it will remain valid for twelve months.